Anti-inflammatory activity of chrysophanol through the suppression of NF-κB/caspase-1 activation in vitro and in vivo

Molecules

Volumn 15, Issue 9, 2010, Pages 6436-6451

  Kim, Su Jin ^a   Kim, Min Cheol ^b   Lee, Byong Joo ^a   Park, Dae Hee ^a   Hong, Seung Heon ^b   Um, Jae Young ^a  

^a Kyung Hee University   (South Korea)

^b Wonkwang University   (South Korea)

Author keywords

Chrysophanol; Colitis; Inflammation; Macrophage

Indexed keywords

ANTHRAQUINONE DERIVATIVE; ANTIINFLAMMATORY AGENT; CHRYSOPHANIC ACID; DEXTRAN SULFATE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA CONVERTING ENZYME; LIPOPOLYSACCHARIDE; MUTAGENIC AGENT;

ANIMAL; ARTICLE; CELL LINE; CHEMICALLY INDUCED DISORDER; COLITIS; DRUG ANTAGONISM; DRUG EFFECT; INFLAMMATION; MOUSE; PATHOLOGY; PERITONEUM MACROPHAGE; TREATMENT OUTCOME;

ANIMALS; ANTHRAQUINONES; ANTI-INFLAMMATORY AGENTS; CASPASE 1; CELL LINE; COLITIS; DEXTRAN SULFATE; INFLAMMATION; LIPOPOLYSACCHARIDES; MACROPHAGES, PERITONEAL; MICE; MUTAGENS; NF-KAPPA B; TREATMENT OUTCOME;

EID: 77957296084     PISSN: None     EISSN: 14203049     Source Type: Journal    
DOI: 10.3390/molecules15096436     Document Type: Article

References (34)

1. Medzhitov, R.; Janeway, C. A. Jr. Innate immunity: the virtues of a nonclonal system of recognition. Cell 1997, 9, 295-298.
2. Beutler, B. TNF, Tlr4: central component of the sole mammalian LPS sensor. Curr. Opin. Immunol. 2000, 12, 20-26.
3. Beutler, B. TNF, immunity and inflammatory disease: lessons of the past decade. J. Investig. Med. 1995, 43, 227-235.
4. Parrillo, J. E. Pathogenetic mechanisms of septic shock. N. Engl. J. Med. 1993, 328, 1471-1477.
5. Papadakis, K. A.; Targan, S. R. Role of cytokines in the pathogenesis of inflammatory bowel disease. Ann. Rev. Med. 2000, 51, 289-298.
6. Rogler, G.; Andus T. Cytokines in inflammatory bowel disease. World J. Surg. 1998, 22, 382-389.
7. Ogata, H.; Hibi, T. Cytokine and anti-cytokine therapies for inflammatory bowel disease. Curr. Pharm. Des. 2003, 9, 1107-1113.
8. Roberts, P. J.; Morgan, K.; Miller, R.; Hunter, J. O.; Middleton, S. J. Neuronal COX-2 expression in human myenteric plexus in active inflammatory bowel disease. Gut 2001, 48, 468-472.
9. Agoff, S. N.; Brentnall, T. A.; Crispin, D. A.; Taylor, S. L.; Raaka, S.; Haggitt, R. C.; Reed, M. W.; Afonina, I. A.; Rabinovitch, P. S.; Stevens, A. C.; Feng, Z.; Bronner, M. P. The role of cyclooxygenase 2 in ulcerative colitis-associated neoplasia. Am. J. Pathol. 2000, 157, 737-745.
10. Baldwin, A. S. Jr. The NF-kappa B and I kappa B proteins: new discoveries and insights. Ann. Rev. Immunol. 1996, 14, 649-683.
11. Finco, T.; Baldwin, A. S., Jr. Mechanistic aspects of NF-kB regulation: the emerging role of phosphorylation and proteolysis. Immunity 1995, 3, 263-272.
12. Neurath, M. F.; Fuss, I.; Schurmann, G.; Pettersson, S.; Arnold, K.; Müller-Lobeck, H.; Strober, W.; Herfarth, C.; Büschenfelde, K. H. Cytokine gene transcription by NF-kB family members in patients with inflammatory bowel disease. Ann. NY Acad. Sci. 1998, 859, 149-159.
13. Schreiber, S.; Nikolaus, S.; Hampe, J. Activation of nuclear factor kappa B in inflammatory bowel disease. Gut 1998, 42, 477-484. (Pubitemid 28186562)
14. Lee, S. H.; Stehlik, C.; Reed, J. C. Cop, a caspase recruitment domaincontaining protein and inhibitor of caspase-1 activation processing. J. Biol. Chem. 2001, 276, 34495-34500.
15. Wang, X.; Wang, H. Y.; Bryan, E. F.; Zhang, W. H.; Huo, C. F.; Guan, Y. J.; Zhang, Y.; Bruey, J. M.; John, C. R.; Robert, M. F. Dysregulation of receptor interacting protein-2 and caspase recruitment domain only protein mediates aberrant caspase-1 activation in Huntington's disease. J. Neurosci. 2005, 25, 11645-11654.
16. Faubel, S.; Lewis, E. C.; Reznikov, L.; Ljubanovic, D.; Hoke, T. S.; Somerset, H.; Oh, D. J.; Lu, L.; Klein, C. L.; Dinarello, C. A.; Edelstein, C. L. Cisplatin-induced acute renal failure is associated with an increase in the cytokines interleukin (IL)-1beta, IL-18, IL-6, and neutrophil infiltration in the kidney. J. Pharmacol. Exp. Ther. 2007, 322, 8-15.
17. Siegmund, B.; Lehr, H. A.; Fantuzzi, G.; Dinarello, C. A. IL-1 beta-converting enzyme (caspase-1) in intestinal inflammation. Proc. Natl. Acad. Sci. USA 2001, 6, 13249-13254.
18. Huang, Q.; Lu, G.; Shen, H. M.; Chung, M. C.; Ong, C. N. Anti-cancer properties of anthraquinones from rhubarb. Med. Res. Rev. 2007, 27, 609-630.
19. Shoemaker, M.; Hamilton, B.; Dairkee, S. H.; Cohen, I.; Campbell, M. J. In vitro anticancer activity of twelve Chinese medicinal herbs. Phytother. Res. 2005, 19, 649-651.
20. Arosio, B.; Gagliano, N.; Fusaro, L. M.; Parmeggiani, L.; Tagliabue, J.; Galetti, P. Aloe-Emodin quinone pretreatment reduces acute liver injury induced by carbon tetrachloride. Pharmacol. toxicol. 2000, 87, 229-233.
21. Fosse, C.; Le Texier, L.; Roy, S.; Delaforge, M.; Grégoire, S.; Neuwels M.; Azerad, R. Parameters and mechanistic studies on the oxidative ring cleavage of synthetic heterocyclic naphthoquinones by Streptomyces strains. Appl. Microbiol. Biotechnol. 2004, 65, 446-456.
22. Cooper, H. S.; Murthy, S. N.; Shah, R. S.; Sedergran, D. J. Clinicopathologic study of dextran sulfate sodium experimental murine colitis. Lab. Invest. 1993, 69, 238-249.
23. Okayasu, I.; Hatakeyama, S.; Yamada, M.; Ohkusa, T.; Inagaki, Y.; Nakaya, R. Novel method in the induction of reliable experimental acute and chronic ulcerative colitis in mice. Gastroenterology 1990, 98, 694-702.
24. Murthy, S. N.; Cooper, H. S.; Shim, H.; Shah, R. S.; Ibarahim, S. A.; Sedergran, D. J. Treatment of dextran sulfate sodium-induced murine colitis by intracolonic cyclosporin. Dig. Dis. Sci. 1993, 38, 1722-1734.
25. Ghosh, S.; May, M. J.; Kopp, E. B. NF-kappa B and Rel proteins: evolutionarily conserved mediators of immune responses. Ann. Rev. Immunol. 1998, 16, 225-260.
26. Bouma, G.; Strober, W. Theimmunological and genetic basis of inflammatory bowel disease. Nat. Rev. Immunol. 2003, 3, 521-533.
27. Ishiguro, K.; Ando, T.; Maeda, O.; Hasegawa, M.; Kado-matsu, K.; Ohmiya, N.; Niwa, Y.; Xavier, R.; Goto, H. Paeonol attenuates TNBS-induced colitis by inhibiting NF-kappaB and STAT1 transactivation. Toxicol. Appl. Pharmacol. 2006, 217, 35-42.
28. Sandborn, W. J.; Targan, S. R. Biologic therapy of inflammatory bowel disease. Gastroenterology 2002, 122, 1592-1608.
29. Loher, F.; Bauer, C.; Landauer, N.; Schmall, K.; Siegmund, B.; Lehr, H. A.; Dauer, M.; Schoenharting, M.; Endres, S.; Eigler, A. The interleukin-1 beta-converting enzyme inhibitor pralnacasan reduces dextran sulfate sodium-induced murine colitis and T helper 1 T-cell activation. J. Pharmacol. Exp. Ther. 2004, 308, 583-590.
30. Lamkanfi, M.; Kalai, M.; Saelens, X.; Declercq, W.; Vandenabeele, P. Caspase-1 activates nuclear factor of the kappa-enhancer in B cells independently of its enzymatic activity. J. Biol. Chem. 2004, 4, 24785-24793.
31. Narumi, S.; Finke, J. H.; Hamilton, T. A. Interferon gamma and interleukin 2 synergize to induce selective monokine expression in murine peritoneal macrophages. J. Biol. Chem. 1990, 265, 7036-7041.
32. Hendrickson, B. A.; Gokhale, R.; Cho, J. H. Clinical aspects and pathophysiology of inflammatory bowel disease. Clin. Microbiol. Rev. 2002, 15, 79-94.
33. Kim, M. S.; Lim, W. K.; Cha, J. G.; An, N. H.; Yoo, S. J.; Park, J. H.; Kim, H. M.; Lee, Y. M. The activation of PI 3-K and PKC zeta in PMA-induced differentiation of HL-60 cells. Cancer Lett. 2001, 171, 79-85.
34. Schoonbroodt, S.; Legrand-Poels, S.; Best-Belpomme, M.; Piette, J. Activation of the NF-kappaB transcription factor in a T-lymphocytic cell line by hypochlorous acid. Biochem. J. 1997, 321, 777-785.